Hemogenyx Confirms "Humanised" Mice Patent Filing As Shares Rocket

LONDON (Alliance News) - Hemogenyx Pharmaceuticals PLC confirmed Monday it has filed a ...

Alliance News 26 February, 2018 | 4:23PM
Email Form

LONDON (Alliance News) - Hemogenyx Pharmaceuticals PLC confirmed Monday it has filed a provisional patent application for its development of a new type of "humanised" mice.

The mice, it said, have a chimeric mouse-human blood system which can be used to advance product development, disease modelling, and drug development.

The announcement on Monday was in response to the company's shares almost trebling Monday, rising to 5.94 pence each from 2.40p at the start of the day's trading.

The movement, Hemogenyx said, was due to a "premature disclosure which the company regrets and is not in accordance with the company's policies on the release of information".

Chief Executive Vladislav Sandler said: "We are hugely excited by the first solid data that we've received testing the efficacy of CDX antibodies against acute myelogenous leukaemia. The results which show that they can attack and eliminate AML cells is a true breakthrough and a significant development in our process of developing CDX to become a universally available conditioning product for patients undergoing bone marrow transplants as a treatment for serious blood diseases.

"In addition the new type of humanised mice opens the door to extending our work into other disease models and specific drug development which we expect to be of great interest to large biopharmaceutical companies and could form the basis of a number of significant future collaborations."

By George Collard; georgecollard@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar
Rating
Hemogenyx Pharmaceuticals PLC 2.53 GBX 0.00 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites